WHA Statement on United Nations Political Declaration on HIV 2021

The United Nations hosted a high-level meeting (HLM) on HIV/AIDS from 8 -10 June 2021. At the conclusion of the meeting, countries signed a political declaration on HIV reaffirming their commitments to ending the HIV epidemic by 2030.

In the document, hepatitis integration is included in several areas, including maternal health interventions, harm reduction services, and services targeting those living with hepatitis co-infection. Across the world, 2.3 million people live with HIV and hepatitis C and 2.7 million people live with HIV and hepatitis B.

The World Hepatitis Alliance (WHA) and our network of over 300 organisations in 100 countries welcome the inclusion of viral hepatitis within the 2021 Political Declaration on HIV/AIDS. Viral hepatitis and HIV often disproportionately affect the same communities. Targeted interventions to help prevent, diagnose, and treat hepatitis and HIV are crucial in ensuring the communities most underserved by health systems are not left behind as we look to tackle these epidemics.

Now is the time to turn these commitments into equitable action on hepatitis elimination. Communities affected by viral hepatitis are often left unable to receive the care they need. We call on global funders to support countries to integrate services, particularly in maternal health and harm reduction services. By taking a person-centred approach to healthcare, with civil society and the affected community playing a central role, we can win the fight against HIV and hepatitis together.

Hepatitis Can’t Wait. We must act now.

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close